AstraZeneca abandons mRNA therapy for heart disease with Moderna
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
AstraZeneca abandons mRNA therapy for heart disease with Moderna after positive Phase 2 clinical trials
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
AstraZeneca abandons mRNA therapy for heart disease with Moderna after positive Phase 2 clinical trials.
AstraZeneca axed a cardiovascular disease candidate developed in partnership with Moderna from its Phase 2 clinical pipeline .
The pharma giant dropped the mRNA therapy a few months after reporting positive results. But the therapy is still in Moderna’s pipeline.
The AstraZeneca- Moderna drug candidate is AZD8601, a therapy based on mRNA encoding vascular endothelial growth factor A (VEGF-A) .
In a phase 2a clinical trial reported late last year, researchers injected mRNA encoding VEGF-A directly into the heart muscle of patients undergoing coronary artery bypass surgery .
Seven patients received AZD8601 and four received a placebo.
VEGF-A acts as a paracrine factor involved in the formation of new blood vessels and in the production of specialized cells that contribute to cardiac repair and regeneration.
AstraZeneca has said the treatment has achieved positive results, with AZD8601 meeting the primary endpoints of safety and tolerability.
or exploratory efficacy endpoints, numerical trends were observed in the treatment group compared with placebo in the heart failure efficacy domain endpoints, including increased left ventricular ejection fraction (LVEF) and functional patient-reported outcomes.
Seven patients treated with AZD8601 had levels of NT-proBNP , a biomarker that measures elevated hormone levels in heart failure patients, below the heart failure limit within 6 months of follow-up , compared with 1 in the placebo group The patient is above the limit.
However, AstraZeneca dropped the Phase 2 therapy in its quarterly update, and AZD8601 co-developer Moderna still lists the therapy in its pipeline.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.